Smith-Bindman Rebecca, Wang Yifei, Nelson Thomas R, Moghadassi Michelle, Wilson Nicole, Gould Robert, Seibert Anthony, Boone John M, Krishnam Mayil, Lamba Ramit, Hall David J, Miglioretti Diana L
From the Department of Radiology and Biomedical Imaging (R.S., M.M., N.W., R.G.), Department of Epidemiology and Biostatistics (R.S.), and Philip R. Lee Institute for Health Policy Studies (R.S.), University of California, San Francisco, 350 Parnassus Ave, Suite 307C, San Francisco, CA 94143-0336; Division of Biostatistics, Department of Public Health Sciences (Y.W., D.L.M.), and Department of Radiology (A.S., J.M.B., R.L.), University of California, Davis, Davis, Calif; Department of Radiology, University of California, San Diego, San Diego, Calif (T.R.Y., D.J.H.); Department of Radiological Sciences, University of California, Irvine, Orange County, Calif (M.K.); and Group Health Research Institute, Group Health Cooperative, Seattle, Wash (D.L.M.).
Radiology. 2017 Jan;282(1):182-193. doi: 10.1148/radiol.2016151391. Epub 2016 Jul 20.
Purpose To determine patient, vendor, and institutional factors that influence computed tomography (CT) radiation dose. Materials and Methods The relevant institutional review boards approved this HIPAA-compliant study, with waiver of informed consent. Volume CT dose index (CTDI) and effective dose in 274 124 head, chest, and abdominal CT examinations performed in adult patients at 12 facilities in 2013 were collected prospectively. Patient, vendor, and institutional characteristics that could be used to predict (a) median dose by using linear regression after log transformation of doses and (b) high-dose examinations (top 25% of dose within anatomic strata) by using modified Poisson regression were assessed. Results There was wide variation in dose within and across medical centers. For chest CTDI, overall median dose across all institutions was 11 mGy, and institutional median dose was 7-16 mGy. Models including patient, vendor, and institutional factors were good for prediction of median doses (R = 0.31-0.61). The specific institution where the examination was performed (reflecting the specific protocols used) accounted for a moderate to large proportion of dose variation. For chest CTDI, unadjusted median CTDI was 16.5 mGy at one institution and 6.7 mGy at another (adjusted relative median dose, 2.6 mGy [95% confidence interval: 2.5, 2.7]). Several variables were important predictors that a patient would undergo high-dose CT. These included patient size, the specific institution where CT was performed, and the use of multiphase scanning. For example, while 49% of patients (21 411 of 43 696) who underwent multiphase abdominal CT had a high-dose examination, 8% of patients (4977 of 62 212) who underwent single-phase CT had a high-dose examination (adjusted relative risk, 6.20 [95% CI: 6.17, 6.23]). If all patients had been examined with single-phase CT, 69% (18 208 of 26 388) of high-dose examinations would have been eliminated. Patient size, institutional-specific protocols, and multiphase scanning were the most important predictors of dose (change in R = 8%-32%), followed by manufacturer and iterative reconstruction (change in R, 0.2%-15.0%). Conclusion CT doses vary considerably within and across facilities. The primary factors that influenced dose variation were multiphase scanning and institutional protocol choices. It is unknown if the variation in these factors influenced diagnostic accuracy. RSNA, 2016.
目的 确定影响计算机断层扫描(CT)辐射剂量的患者、设备供应商及机构因素。材料与方法 相关机构审查委员会批准了这项符合健康保险流通与责任法案(HIPAA)的研究,并豁免了知情同意。前瞻性收集了2013年在12家机构对成年患者进行的274124次头部、胸部及腹部CT检查的容积CT剂量指数(CTDI)和有效剂量。评估了可用于预测以下两项的患者、设备供应商及机构特征:(a)在对剂量进行对数转换后,通过线性回归预测中位剂量;(b)通过修正泊松回归预测高剂量检查(解剖部位内剂量最高的25%)。结果 各医疗中心内部及之间的剂量存在很大差异。对于胸部CTDI,所有机构的总体中位剂量为11 mGy,机构中位剂量为7 - 16 mGy。包含患者、设备供应商及机构因素的模型对中位剂量的预测效果良好(R = 0.31 - 0.61)。进行检查的具体机构(反映所使用的特定方案)占剂量差异的比例适中至很大。对于胸部CTDI,一个机构未调整的中位CTDI为16.5 mGy,另一个机构为6.7 mGy(调整后的相对中位剂量为2.6 mGy [95%置信区间:2.5, 2.7])。有几个变量是患者接受高剂量CT检查的重要预测因素。这些因素包括患者体型、进行CT检查的具体机构以及多期扫描的使用。例如,在接受多期腹部CT检查的患者中,49%(43696例中的21411例)进行了高剂量检查,而在接受单期CT检查的患者中,8%(62212例中的4977例)进行了高剂量检查(调整后的相对风险为6.20 [95%置信区间:6.17, 6.23])。如果所有患者都接受单期CT检查,69%(26388例中的18208例)的高剂量检查本可避免。患者体型、机构特定方案和多期扫描是剂量最重要的预测因素(R变化 = 8% - 32%),其次是制造商和迭代重建(R变化,0.2% - 15.0%)。结论 各机构内部及之间的CT剂量差异很大。影响剂量差异的主要因素是多期扫描和机构方案选择。这些因素的差异是否影响诊断准确性尚不清楚。RSNA,2016年。